{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T02:10:15Z","timestamp":1792375815626,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T00:00:00Z","timestamp":1357862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T00:00:00Z","timestamp":1357862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s11940-012-0210-9","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T05:43:28Z","timestamp":1357796608000},"page":"210-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Treatment Options in Paraneoplastic Disorders of the Peripheral Nervous System"],"prefix":"10.1007","volume":"15","author":[{"given":"Jean-Christophe","family":"Antoine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Camdessanch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,11]]},"reference":[{"issue":"1","key":"210_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1474-4422(06)70679-2","volume":"6","author":"JC Antoine","year":"2007","unstructured":"Antoine JC, Camdessanche JP. Peripheral nervous system involvement in patients with cancer. Lancet Neurol. 2007;6(1):75\u201386.","journal-title":"Lancet Neurol"},{"issue":"8","key":"210_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","volume":"75","author":"F Graus","year":"2004","unstructured":"Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"210_CR3","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/archneurol.2009.341","volume":"67","author":"B Giometto","year":"2010","unstructured":"Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G. Paraneoplastic neurologic syndrome in the PNS euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67(3):330\u20135.","journal-title":"Arch Neurol"},{"issue":"2","key":"210_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/1531-8249(199902)45:2<162::AID-ANA5>3.0.CO;2-R","volume":"45","author":"B Benyahia","year":"1999","unstructured":"Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol. 1999;45(2):162\u20137.","journal-title":"Ann Neurol"},{"issue":"3","key":"210_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/ni0303-201","volume":"4","author":"RB Darnell","year":"2003","unstructured":"Darnell RB, Posner JB. Observing the invisible: successful tumor immunity in humans. Nat Immunol. 2003;4(3):201.","journal-title":"Nat Immunol"},{"issue":"2","key":"210_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1212\/WNL.0b013e318224afde","volume":"77","author":"E Lancaster","year":"2011","unstructured":"Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77(2):179\u201389.","journal-title":"Neurology"},{"issue":"10","key":"210_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.neurol.2011.08.001","volume":"167","author":"J Honnorat","year":"2011","unstructured":"Honnorat J, Viaccoz A. New concepts in paraneoplastic neurological syndromes. Rev Neurol (Paris). 2011;167(10):729\u201336.","journal-title":"Rev Neurol (Paris)"},{"issue":"6","key":"210_CR8","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/jnnp-2011-301237","volume":"83","author":"L Zuliani","year":"2012","unstructured":"Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry. 2012;83(6):638\u201345.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"210_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0092-8674(91)90184-Z","volume":"67","author":"A Szabo","year":"1991","unstructured":"Szabo A, Dalmau J, Manley G, Rosenfeld M, Wong E, Henson J, et al. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to elav and sex-lethal. Cell. 1991;67(2):325\u201333.","journal-title":"Cell"},{"issue":"Pt 7","key":"210_CR10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/brain\/awp136","volume":"132","author":"JP Camdessanche","year":"2009","unstructured":"Camdessanche JP, Jousserand G, Ferraud K, Vial C, Petiot P, Honnorat J, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case\u2013control study. Brain. 2009;132(Pt 7):1723\u201333.","journal-title":"Brain"},{"issue":"3","key":"210_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1529-8027.2012.00411.x","volume":"17","author":"JP Camdessanche","year":"2012","unstructured":"Camdessanche JP, Jousserand G, Franques J, Pouget J, Delmont E, Creange A, et al. A clinical pattern-based etiological diagnostic strategy for sensory neuronopathies: a French collaborative study. J Peripher Nerv Syst. 2012;17(3):331\u201340. This paper provides a controlled strategy for the etiological diagnosis of sensory neuronopathy identified by the diagnosis criteria published in reference 10 allowing distinguishing paraneoplastic from non paraneoplastic forms.","journal-title":"J Peripher Nerv Syst"},{"issue":"Pt 6","key":"210_CR12","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","volume":"124","author":"F Graus","year":"2001","unstructured":"Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124(Pt 6):1138\u201348.","journal-title":"Brain"},{"issue":"4","key":"210_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/NEN.0b013e31824d1df2","volume":"71","author":"JP Camdessanche","year":"2012","unstructured":"Camdessanche JP, Ferraud K, Boutahar N, Lassabliere F, Mutter M, Touret M, et al. The collapsin response mediator protein 5 onconeural protein is expressed in Schwann cells under axonal signals and regulates axon-Schwann cell interactions. J Neuropathol Exp Neurol. 2012;71(4):298\u2013311.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"210_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/jnnp.2007.138016","volume":"80","author":"J Honnorat","year":"2009","unstructured":"Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2\/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2009;80(4):412\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"210_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/0166-2236(89)90109-4","volume":"12","author":"A Vincent","year":"1989","unstructured":"Vincent A, Lang B, Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 1989;12(12):496\u2013502.","journal-title":"Trends Neurosci"},{"issue":"Pt 3","key":"210_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/brain\/111.3.577","volume":"111","author":"JH O'Neill","year":"1988","unstructured":"O'Neill JH, Murray NM, Newsom-Davis J. The lambert-aton myasthenic syndrome. A review of 50 cases. Brain. 1988;111(Pt 3):577\u201396.","journal-title":"Brain"},{"issue":"4","key":"210_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0303-8467(02)00054-9","volume":"104","author":"PW Wirtz","year":"2002","unstructured":"Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104(4):359\u201363.","journal-title":"Clin Neurol Neurosurg"},{"issue":"22","key":"210_CR18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","volume":"332","author":"VA Lennon","year":"1995","unstructured":"Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel antibodies in the lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332(22):1467\u201374.","journal-title":"N Engl J Med"},{"issue":"5","key":"210_CR19","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/WNL.48.5.1261","volume":"48","author":"M Takamori","year":"1997","unstructured":"Takamori M, Iwasa K, Komai K. Antibodies to synthetic peptides of the alpha1a subunit of the voltage-gated calcium channel in lambert-Eaton myasthenic syndrome. Neurology. 1997;48(5):1261\u20135.","journal-title":"Neurology"},{"issue":"1","key":"210_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","volume":"147","author":"M Motomura","year":"1997","unstructured":"Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the lambert-eaton myasthenic syndrome. J Neurol Sci. 1997;147(1):35\u201342.","journal-title":"J Neurol Sci"},{"issue":"12","key":"210_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1212\/01.wnl.0000281663.81079.24","volume":"70","author":"L Sabater","year":"2008","unstructured":"Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. Sox1 antibodies are markers of paraneoplastic lambert-Eaton myasthenic syndrome. Neurology. 2008;70(12):924\u20138.","journal-title":"Neurology"},{"issue":"26","key":"210_CR22","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1200\/JCO.2008.20.6169","volume":"27","author":"MJ Titulaer","year":"2009","unstructured":"Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, et al. Sox 1 antibodies in small-cell lung cancer and lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009;27(26):4260\u20137.","journal-title":"J Clin Oncol"},{"issue":"10","key":"210_CR23","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1212\/WNL.42.10.1944","volume":"42","author":"PD Clouston","year":"1992","unstructured":"Clouston PD, Saper CB, Arbizu T, Johnston I, Lang B, Newsom-Davis J, et al. Paraneoplastic cerebellar degeneration. Iii. Cerebellar degeneration, cancer, and the lambert-Eaton myasthenic syndrome. Neurology. 1992;42(10):1944\u201350.","journal-title":"Neurology"},{"issue":"10 Suppl 4","key":"210_CR24","doi-asserted-by":"publisher","first-page":"S277","DOI":"10.1097\/JTO.0b013e3181f23f04","volume":"5","author":"A Vincent","year":"2010","unstructured":"Vincent A, Irani SR. Caspr2 antibodies in patients with thymomas. J Thorac Oncol. 2010;5(10 Suppl 4):S277\u201380.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"210_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ana.22297","volume":"69","author":"E Lancaster","year":"2011","unstructured":"Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A, Martinez-Hernandez E, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011;69(2):303\u201311. This paper identifies CASPR 2 as the main target of antibodies in neuromyotonia.","journal-title":"Ann Neurol"},{"issue":"4","key":"210_CR26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/WCO.0b013e328347b307","volume":"24","author":"J Panzer","year":"2011","unstructured":"Panzer J, Dalmau J. Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol. 2011;24(4):346\u201353.","journal-title":"Curr Opin Neurol"},{"issue":"Pt 8","key":"210_CR27","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/brain\/awf178","volume":"125","author":"IK Hart","year":"2002","unstructured":"Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain. 2002;125(Pt 8):1887\u201395.","journal-title":"Brain"},{"issue":"5","key":"210_CR28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/ana.410380505","volume":"38","author":"P Shillito","year":"1995","unstructured":"Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, et al. Acquired neuromyotonia: evidence for autoantibodies directed against k+ channels of peripheral nerves. Ann Neurol. 1995;38(5):714\u201322.","journal-title":"Ann Neurol"},{"issue":"3","key":"210_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/(SICI)1097-4598(199703)20:3<299::AID-MUS6>3.0.CO;2-6","volume":"20","author":"K Arimura","year":"1997","unstructured":"Arimura K, Watanabe O, Kitajima I, Suehara M, Minato S, Sonoda Y, et al. Antibodies to potassium channels of pc12 in serum of Isaacs' syndrome: Western blot and immunohistochemical studies. Muscle Nerve. 1997;20(3):299\u2013305.","journal-title":"Muscle Nerve"},{"issue":"9","key":"210_CR30","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1093\/brain\/awq213","volume":"133","author":"SR Irani","year":"2010","unstructured":"Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734\u201348.","journal-title":"Brain"},{"issue":"2","key":"210_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ana.23577","volume":"72","author":"SR Irani","year":"2012","unstructured":"Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72(2):241\u201355. An important study on the rare Morvan syndrome.","journal-title":"Ann Neurol"},{"issue":"8","key":"210_CR32","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","volume":"9","author":"M Lai","year":"2010","unstructured":"Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of Lgi1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776\u201385. This paper identifies LGI1 as the actual target of antibodies in a subgroup of patients with limbic encephalitis.","journal-title":"Lancet Neurol"},{"issue":"8","key":"210_CR33","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1212\/WNL.53.8.1719","volume":"53","author":"F Keime-Guibert","year":"1999","unstructured":"Keime-Guibert F, Graus F, Broet P, Rene R, Molinuevo JL, Ascaso C, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology. 1999;53(8):1719\u201323.","journal-title":"Neurology"},{"issue":"7","key":"210_CR34","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1468-1331.2006.01266.x","volume":"13","author":"CA Vedeler","year":"2006","unstructured":"Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, et al. Management of paraneoplastic neurological syndromes: report of an EFNS task force. Eur J Neurol. 2006;13(7):682\u201390.","journal-title":"Eur J Neurol"},{"issue":"1","key":"210_CR35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/jnnp.2008.159483","volume":"81","author":"D Psimaras","year":"2010","unstructured":"Psimaras D, Carpentier AF, Rossi C. CSF study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry. 2010;81(1):42\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"210_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1468-1331.2010.03220.x","volume":"18","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19\u2013e13. This paper provides recommendation on the best strategy to develop to obtain an early diagnosis of the cancer.","journal-title":"Eur J Neurol"},{"issue":"4","key":"210_CR37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/jnnp.60.4.388","volume":"60","author":"M Uchuya","year":"1996","unstructured":"Uchuya M, Graus F, Vega F, Rene R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996;60(4):388\u201392.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3 Pt 1","key":"210_CR38","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1212\/WNL.42.3.536","volume":"42","author":"F Graus","year":"1992","unstructured":"Graus F, Vega F, Delattre JY, Bonaventura I, Rene R, Arbaiza D, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology. 1992;42(3 Pt 1):536\u201340.","journal-title":"Neurology"},{"issue":"8","key":"210_CR39","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/archneur.1995.00540320098016","volume":"52","author":"E Stark","year":"1995","unstructured":"Stark E, Wurster U, Patzold U, Sailer M, Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol. 1995;52(8):814\u20138.","journal-title":"Arch Neurol"},{"issue":"1","key":"210_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/1531-8249(200001)47:1<9::AID-ANA5>3.0.CO;2-I","volume":"47","author":"ML Albert","year":"2000","unstructured":"Albert ML, Austin LM, Darnell RB. Detection and treatment of activated t cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000;47(1):9\u201317.","journal-title":"Ann Neurol"},{"issue":"1","key":"210_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00415-005-0882-0","volume":"253","author":"S Shams'ili","year":"2006","unstructured":"Shams'ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, Van\u2019t Veer M, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006;253(1):16\u201320.","journal-title":"J Neurol"},{"issue":"4","key":"210_CR42","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/jnnp.68.4.479","volume":"68","author":"F Keime-Guibert","year":"2000","unstructured":"Keime-Guibert F, Graus F, Fleury A, Rene R, Honnorat J, Broet P, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68(4):479\u201382.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"210_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1215\/S1152851703000395","volume":"6","author":"S Vernino","year":"2004","unstructured":"Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol. 2004;6(1):55\u201362.","journal-title":"Neuro Oncol"},{"issue":"3","key":"210_CR44","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1212\/WNL.47.3.678","volume":"47","author":"PG Bain","year":"1996","unstructured":"Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the lambert-Eaton myasthenic syndrome. Neurology. 1996;47(3):678\u201383.","journal-title":"Neurology"},{"issue":"9S","key":"210_CR45","first-page":"S17","volume":"5","author":"J Newsom-Davis","year":"1982","unstructured":"Newsom-Davis J, Murray N, Wray D, Lang B, Prior C, Gwilt M, et al. Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor. Muscle Nerve. 1982;5(9S):S17\u201320.","journal-title":"Muscle Nerve"},{"issue":"6","key":"210_CR46","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","volume":"82","author":"P Maddison","year":"2011","unstructured":"Maddison P, McConville J, Farrugia ME, Davies N, Rose M, Norwood F, et al. The use of rituximab in myasthenia gravis and lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82(6):671\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"210_CR47","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113\u2013e1188. An interesting review of the different treatment of neuropathic pain with guidelines.","journal-title":"Eur J Neurol"},{"issue":"23","key":"210_CR48","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"KM McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-diaminopyridine in the treatment of lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321(23):1567\u201371.","journal-title":"N Engl J Med"},{"issue":"5","key":"210_CR49","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/mus.21422","volume":"40","author":"SJ Oh","year":"2009","unstructured":"Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve. 2009;40(5):795\u2013800.","journal-title":"Muscle Nerve"},{"issue":"3","key":"210_CR50","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/WNL.54.3.603","volume":"54","author":"DB Sanders","year":"2000","unstructured":"Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in lambert-Eaton myasthenic syndrome. Neurology. 2000;54(3):603\u20137.","journal-title":"Neurology"},{"issue":"1","key":"210_CR51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/clpt.2009.35","volume":"86","author":"PW Wirtz","year":"2009","unstructured":"Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86(1):44\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"210_CR52","first-page":"CD003279","volume":"2","author":"M Keogh","year":"2011","unstructured":"Keogh M, Sedehizadeh S, Maddison P. Treatment for lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011;2:CD003279. An excellent review of the available evidence for the treatment of LEMS completed with a meta-analysis.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"210_CR53","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893\u2013902. This paper provides guidelines for the management of LEMS and PNH.","journal-title":"Eur J Neurol"},{"issue":"9","key":"210_CR54","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","volume":"15","author":"I Elovaara","year":"2008","unstructured":"Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: efns task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893\u2013908.","journal-title":"Eur J Neurol"},{"issue":"23","key":"210_CR55","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1212\/01.wnl.0000313840.27060.bf","volume":"70","author":"MC Dalakas","year":"2008","unstructured":"Dalakas MC. Invited article: inhibition of B cell functions: implications for Neurology. Neurology. 2008;70(23):2252\u201360.","journal-title":"Neurology"},{"issue":"4","key":"210_CR56","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.amjmed.2011.09.010","volume":"125","author":"M Ramos-Casals","year":"2012","unstructured":"Ramos-Casals M, Sanz I, Bosch X, Stone JH, Khamashta MA. B-cell-depleting therapy in systemic lupus erythematosus. Am J Med. 2012;125(4):327\u201336.","journal-title":"Am J Med"},{"issue":"12","key":"210_CR57","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/j.1469-0691.2011.03653.x","volume":"17","author":"E Tavazzi","year":"2011","unstructured":"Tavazzi E, Ferrante P, Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect. 2011;17(12):1776\u201380.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"210_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","volume":"10","author":"J Dalmau","year":"2011","unstructured":"Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63\u201374.","journal-title":"Lancet Neurol"},{"issue":"6","key":"210_CR59","first-page":"732","volume":"20","author":"F Graus","year":"2007","unstructured":"Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol. 2007;20(6):732\u20137.","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"210_CR60","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00019053-200927020-00002","volume":"27","author":"AB O'Connor","year":"2009","unstructured":"O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009;27(2):95\u2013112.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"210_CR61","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/cc10312","volume":"15","author":"RA Hughes","year":"2011","unstructured":"Hughes RA. Give or take? Intravenous immunoglobulin or plasma exchange for Guillain-Barr\u00e9 syndrome. Crit Care. 2011;15(4):174.","journal-title":"Crit Care"},{"key":"210_CR62","first-page":"CD003906","volume":"9","author":"MM Mehndiratta","year":"2012","unstructured":"Mehndiratta MM, Hughes RA. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2012;9:CD003906.","journal-title":"Cochrane Database Syst Rev"},{"key":"210_CR63","first-page":"CD002275","volume":"4","author":"P Gajdos","year":"2002","unstructured":"Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002;4:CD002275.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-012-0210-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0210-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-012-0210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:02:10Z","timestamp":1744149730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-012-0210-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,11]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["210"],"URL":"https:\/\/doi.org\/10.1007\/s11940-012-0210-9","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,11]]},"assertion":[{"value":"11 January 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}